DOCK10: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: DOCK10

NCBI ID: G55619

DOCK10

DOCK10: A Potential Drug Target and Biomarker for Prostate Cancer

Prostate cancer is a leading cause of cancer-related deaths worldwide, with an estimated 17 million new cases and 9 million deaths in 2019, according to the American Cancer Society. Despite advances in cancer treatment, the prognosis for many patients remains poor, highlighting the need for new, effective therapies. One promising candidate for cancer treatment is DOCK10, a protein that has been identified as a potential drug target and biomarker for prostate cancer.

In this article, we will explore the biology of DOCK10 and its potential as a drug target and biomarker for prostate cancer.

The biology of DOCK10

DOCK10 is a protein that is expressed in a variety of tissues, including the prostate, and is involved in several cellular processes. It is a member of the DOCK family of proteins, which are known for their role in intracellular signaling.

DOCK10 functions as a negative regulator of the androgen receptor (AR), a protein that plays a critical role in the development and maintenance of male sexual characteristics. In prostate cancer, the AR is often mutated or over-expressed, leading to the development of cancer. By inhibiting the AR, DOCK10 may be able to reduce the growth and spread of prostate cancer cells.

In addition to its role in regulating the AR, DOCK10 is also involved in the regulation of cell adhesion and migration. It has been shown to play a role in the development of cancer stem cells, which are cells that are capable of self-replication and have the potential to give rise to all types of cancer. By targeting DOCK10 with drugs, researchers may be able to inhibit the development and progression of cancer stem cells.

Potential drug targeting

DOCK10 is a potential drug target for prostate cancer because of its involvement in the AR and cancer stem cell regulation. Drugs that can inhibit the activity of DOCK10 may be effective in treating prostate cancer.

One class of drugs that are known to inhibit the AR is called androgens. Androgens include male hormones such as testosterone, and they are often used to treat prostate cancer in advanced stages. However, androgens have several potential drawbacks, including the risk of masculizing effects, decreased libido, and an increased risk of sexual dysfunction.

To address these concerns, researchers have been exploring new and alternative classes of drugs that can inhibit the AR without the risk of masculizing effects. One such class of drugs is the androgen receptor modulators (ARMs). These drugs work by binding to the AR and modulating its activity, without the risk of masculizing effects.

ARMs have been shown to be effective in treating prostate cancer, and they are often used as a first-line treatment for advanced stages of the disease. However, the ARMs used in these therapies can have several drawbacks, including the risk of decreased libido and decreased sexual function.

DOCK10 as a biomarker

DOCK10 has also been identified as a potential biomarker for prostate cancer. By measuring the level of DOCK10 in prostate tissue samples, researchers may be able to monitor the effectiveness of cancer treatments and identify new biomarkers for prostate cancer.

In addition to its potential as a drug target, DOCK10 has also been shown to be involved in the regulation of cell death. It has been shown to play a role in the production of cell apoptosis (programmed cell death), which is a natural process that helps remove damaged or dysfunctional cells from the body.

By inhibiting cell apoptosis, DOCK10 may have the potential to

Protein Name: Dedicator Of Cytokinesis 10

Functions: Guanine nucleotide-exchange factor (GEF) that activates CDC42 and RAC1 by exchanging bound GDP for free GTP. Essential for dendritic spine morphogenesis in Purkinje cells and in hippocampal neurons, via a CDC42-mediated pathway. Sustains B-cell lymphopoiesis in secondary lymphoid tissues and regulates FCER2/CD23 expression

The "DOCK10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets